L
ower levels of circulating 25-hydroxyvitamin D (25(OH)D) and frailty (a term indicating multisystem impairment and expanding vulnerability) are increasingly common with advancing age. Several previous studies have reported that frailty independently predicts risks of adverse health outcomes including incident disability, falls, fractures, and mortality (1) (2) (3) (4) . Dimensions of frailty including weakness and slowness are potential outcomes of vitamin D deficiency, and lower 25(OH)D levels have been inconsistently associated with poorer physical performance and increased risks of falls, fractures, and death in postmenopausal women and older men (5, 6) .
Previous cross-sectional studies have inconsistently reported that older adults with lower 25(OH)D levels are more likely to be classified as frail as compared with not frail (7, 8) . However, only one previous study (9) expressed frailty status as a continuum ranging from robust to intermediate stage to frail; this study reported an association between lower 25(OH)D levels and greater frailty status among men but not women. Among individuals classified as not frail at baseline, three studies (8, 10) To test the hypothesis that lower 25(OH)D levels at baseline were associated with greater prevalent frailty status, we measured 25(OH)D and assessed frailty status in a cohort of 6307 community-dwelling women aged Ն69 years enrolled in the Study of Osteoporotic Fractures (SOF). To determine whether lower 25(OH)D levels at baseline were associated with an increased risk of greater frailty status at follow-up, 4551 women classified as nonfrail (robust or intermediate) at baseline had frailty status reassessed an average of 4.5 years later.
Materials and Methods

Participants
From September 1986 to October 1988, 9704 women who were Ն65 years were recruited for participation in the baseline examination of the prospective SOF (11) . Women were recruited from population-based listings in four regions of the United States. Black women were originally excluded from SOF because they have a low incidence of hip fracture. In addition, women were excluded if they had a history of bilateral hip replacement or were unable to walk without the assistance of another person.
All surviving participants were invited to attend a Year 6 examination between August 1992 and July 1994. A total of 6818 women (78% of survivors as of July 31, 1994) completed the Year 6 examination and 6350 provided sufficient sera for measurement of 25(OH)D level. Of these, 6307 women (99.3%) provided adequate data for assessment of frailty status and comprised the analytical cohort for the cross-sectional analysis (Fig.  1) . A total of 5242 of the 6307 women were classified as nonfrail (robust or intermediate stage) at baseline and were eligible for the longitudinal analysis. After excluding 691 women (Fig. 1) , the final longitudinal cohort was comprised of 4551 women including 4119 who had repeat assessment of frailty status at a Year 10 examination an average of 4.5 years later and 432 who died before this follow-up examination. The institutional review board at each center approved the study protocol, and written informed consent was obtained from all subjects.
Measurement of 25(OH)D
Fasting morning blood was collected, serum was prepared immediately after phlebotomy, and then was stored at Ϫ70 C. Measures for 25(OH)D 2 (derived from ergocalciferol) and 25(OH)D 3 (derived from cholecalciferol) were performed at the Mayo Clinic using liquid chromatography tandem mass spectroscopy (LC-MS/MS) as previously described (12) . Deuterated stable isotope (d3-25-hydroxyvitamin D) was added to a 0.2 ml serum sample as internal standard. 25(OH)D 2 , 25(OH)D 3 , and the internal standard were extracted using acetonitrile precipitation The extracts were then further purified online and analyzed by LC-MS/MS using multiple reaction monitoring. 25(OH)D 2 and 25(OH)D 3 were quantified and summed for total 25(OH)D. The minimum detectable limit for 25(OH)D 2 was 4 ng/ml and for 25(OH)D 3 was 2 ng/ml. For 25(OH)D 2 , the interassay coefficient of variation (CV) ranged from 4.7% to 6.2% and the intraassay CV ranged from 3.3% to 4.4%. For 25(OH)D 3 , the interassay CV ranged from 5.0% to 6.8% and the intraassay CV ranged from 2.4% to 4.7%.
Other measurements
Participants completed a questionnaire and were interviewed at the examinations and asked about health status, educational achievement, smoking status, and alcohol intake. A selected medical history was obtained that included a history of a phy- sician diagnosis of fracture since the age of 50 years, stroke, cancer excluding skin cancer, dementia, hypertension, parkinsonism, diabetes mellitus, coronary heart disease, and chronic obstructive lung disease. Participants were asked to bring all medications including nonprescription supplements to clinic for verification of use. Total calcium intake (mg/d) was calculated by summing dietary calcium intake (13, 14) and daily dosage of calcium supplements. Physical activity (15) was assessed using a modified version of the Harvard Alumni Questionnaire (16, 17) and expressed as kilocalories expended per week from walking. Depressive symptoms were evaluated using the 15-item Geriatric Depression Scale (18) . Cognitive function was assessed with a modified version of the Mini-Mental State Examination (19) with a maximum score of 26. Tests of physical function included grip strength (using a hand-held Jamar dynamometer) and walk speed (time in seconds to walk 6 m at usual pace). Body weight and height measurements were used to calculate a standard body mass index (BMI).
Frailty status
Frailty status at the Year 6 examination (baseline for this analysis) was defined using the following criteria similar to those proposed by Fried and colleagues (1) Women with none of the above components were considered to be robust, those with one or two components were considered to be in an intermediate stage, and those with Ն3 components were considered to be frail.
Frailty status at the Year 10 (follow-up) examination was defined using criteria cut points from the baseline examination (shrinking/sarcopenia) was identified by weight loss of 5% or more between the Year 8 and 
Statistical analysis
Characteristics of participants at the baseline (Year 6) examination according to category of total 25(OH)D level were compared using ANOVA for normally distributed continuous data, Kruskal-Wallis tests for skewed continuous data, and 2 tests for categorical data.
We used restricted cubic splines to determine whether the association between 25(OH)D level and frailty status at baseline was nonlinear (21, 22) . Knots were placed at the 5th, 25th, 50th, The association between 25(OH)D level and the ordinal frailty status outcome was initially examined using proportional odds models. We evaluated the assumption of homogeneity of effect of 25(OH)D across all levels of the frailty outcome (23) . However, the proportionality assumption was not met in the longitudinal models. Thus for consistency in presenting crosssectional and longitudinal results, two separate logistic regression models were performed for the cross-sectional analyses [ Initial models were adjusted for age, clinic site, season of blood draw, and BMI, then for multiple potential confounders (multivariable model). Factors associated with frailty status at the baseline examination independent of age and those related to 25(OH)D level at P Յ 0.10 at baseline or follow-up examinations were considered for inclusion in the multivariable model. Variables used to define each of the individual frailty components (such as physical activity) were not included in the covariate selection process. Covariates in the cross-sectional multivariable model included age, site, season, BMI, health status, education, smoking status, alcohol intake, number of comorbid medical conditions, and cognitive function. The longitudinal multivariable model was additionally adjusted for baseline frailty status (intermediate vs. robust).
Statistical analyses were completed using SAS v9.2 (SAS Inc., Cary, NC) and Stata v11.0 (Stata Corporation, College Station, TX).
Results
Of the 6307 women in the cohort at baseline, 2195 (34.8%) were classified as robust, 3047 (48.3%) were in Table 1 . The proportion of women classified as frail was 23.5% among women with levels Ͻ15.0 ng/ ml, 17.6% among women with levels 15.0 -19.9 ng/ml, 13.6% women with levels 20.0 -29.9 ng/ml, and 16.0% among the women with levels Ն30.0 ng/ml (P Յ 0.001). A similar U-shaped pattern in the prevalence of frailty across 25(OH)D levels was observed when the cohort was restricted to 3675 women not taking vitamin D supplements at baseline (P Ͻ 0.001). In addition, the prevalence of four individual frailty components (shrinking/sarcopenia, weakness, slowness, low activity level) exhibited Ushaped patterns across category of 25(OH)D level.
Cross-sectional association between 25(OH)D level and frailty status
A nonlinear U-shaped pattern between 25(OH)D level and odds of frailty was confirmed in an analysis using restricted cubic spline models that indicated a nadir of risk among women with levels 20.0 -29.9 ng/ml and increasing odds of frailty at lower and higher values of 25(OH)D (Fig.  2) . The equality of slopes assumption failed for 25(OH)D Ͻ15.0 ng/ml vs. Ն30.0 ng/ml (P ϭ 0.02) and for 25(OH)D 20.0 -29.9 ng/ml vs. Ն30 ng/ml (P Ͻ 0.001) indicating that the association between 25(OH)D and frailty differed above and below this cut point. Findings were similar when 25(OH)D 3 level was substituted for total 25(OH)D in the analysis.
Compared with women with 25(OH)D levels 20.0 -29.9 ng/ml (referent group), the odds of frailty (vs. robust/ intermediate) were higher among those with levels Ͻ15.0 ng/ml [multivariable odds ratio (MOR) 1.47, 95% confidence interval (CI), 1.19 -1.82], those with levels 15.0 -19.9 ng/ml (MOR 1.24, 95% CI 0.99 -1.54), and those with levels Ն30.0 ng/ml (MOR 1.32, 95% CI 1.06 -1.63) ( Table 2 ). The odds ratio of intermediate/frail status (vs. robust) was higher among women with levels Ͻ15.0 ng/ml (MOR 1.30, 95% CI 1.10 -1.53) compared with those with levels 20.0 -29.9 ng/ml, but odds ratios were smaller in magnitude and not significant for those with levels 15.0-19.9 ng/ml and those with levels Ն30.0 ng/ml. When 
25(OH)D 3 was substituted for total 25(OH)D in the analyses, results were unchanged (results not shown).
In addition, findings were in general agreement when 25(OH)D level was expressed in quartiles (cut points 16.0, 22.0, and 29.0 ng/ml) using quartile 3 as the referent group, but the odds ratios reached significance only for women in quartile 1. After adjustment for multiple potential confounders, the odds of each individual frailty component (shrinking/ sarcopenia, weakness, exhaustion, slowness, low activity level) were higher among women with 25(OH)D levels Ͻ15.0 ng/ml compared with women in the referent group (25(OH)D level 20.0 -29.9 ng/ml) ( Table 3) . Women with 25(OH)D 15.0 -19.9 ng/ml and those with levels Ն30 ng/ml had higher odds of weakness. In addition, women with levels 15.0 -19.9 ng/ml and those with levels Ն30 ng/ml appeared to have higher odds of shrinking/sarcopenia, slowness, and low activity level, though none of these associations reached significance.
Longitudinal association between 25(OH)D level and frailty status
A total of 4551 women classified as nonfrail (robust or intermediate) at baseline constituted the longitudinal cohort. At the follow-up examination an average of 4.5 years later, 1041 women (22.9%) were classified as robust, 2330 (51.2%) were in the intermediate stage, 748 (16.4%) were classified as frail, and 432 (9.5%) had died in the interim period. Compared with the longitudinal cohort, the 691 surviving women classified as nonfrail at baseline who did not provide enough data for frailty status assessment at follow-up were, on average, older (77.2 vs. 75.9 years, P Ͻ 0.001) and more likely to be classified as intermediate stage (65.4% vs. 57.0%, P Ͻ 0.001), but were no more likely to report poor to fair health status (14.6% vs. 14.1%, P ϭ 0.70) and had similar 25(OH)D levels (23.0 vs. 23.2 ng/ml, P ϭ 0.20).
Compared with women in the referent group [baseline 25(OH)D levels 20.0 -29.9 ng/ml], the odds of shrinking/sarcopenia at follow-up were higher among women with levels 15.0 -19.9 ng/ml (MOR 1.29, 95% CI 1.03-1.62, P ϭ 0.02) and appeared higher among women with levels Ն30 ng/ml (MOR 1.22, 95% CI 0.98 -1.52, P ϭ 0.07). There was no association between baseline 25(OH)D level and odds of the other individual frailty components at follow-up (data not shown).
In base and multivariable models, there was no evidence of an association between 25(OH)D level at baseline and odds of being classified as intermediate/frail/ dead (vs. robust) at follow-up (Table 4) 
Discussion
Among this cohort of older women, lower (Ͻ20 ng/ml) and higher (Ն30 ng/ml) 25(OH)D levels were moderately associated with a higher odds of frailty at baseline. In addition, lower 25(OH)D levels in nonfrail women at baseline were modestly associated with an increased risk of incident frailty or death at follow-up an average of 4.5 years later. Previous smaller cross-sectional studies including or limited to older women have inconsistently observed an independent association between lower 25(OH)D levels and frailty. The Longitudinal Aging Study Amsterdam (LASA) of 1321 adults Ն65 years old (8) measured serum 25(OH)D using a competitive binding protein assay, defined frailty as the presence of three out of nine frailty indicators, and reported that the odds of being classified as frail (vs. non-frail) was 1.7-fold higher among those with levels between 10 and 20 ng/ml and 2.6-fold higher among those with levels Ͻ10 ng/ml, compared with that among the referent group (Ͼ20 ng/ml). The Women's Heath and Aging Studies (7) measured serum 25(OH)D using a competitive binding protein assay, defined frailty using similar criteria to those used in the CHS index, and found an age-adjusted 1.7-fold higher odds of being classified as frail (vs. non-frail) among women with levels in the lowest quartile (cut point not reported) compared with that among women with levels in the upper three quartiles, but the association did not persist after further adjustment. Finally, the InCHIANTI study of older Italian men and women (9) measured serum 25(OH)D levels using a RIA, defined frailty with a modified CHS index, and reported that lower levels (Ͻ20 ng/ml) were associated with frailty in men, but not in women. While the InCHIANTI study found an independent association between lower 25(OH)D levels (Ͻ20 ng/ml) among women and the presence of only one of five individual frailty components (low activity level), the current study using a similar frailty definition observed independent associations between lower 25(OH)D levels (Ͻ15 ng/ml or in the case of weakness Ͻ20 ng/ml) and the presence of each of five individual frailty dimensions (weakness, shrinking/sarcopenia, exhaustion, slowness, low activity level).
Among women classified as nonfrail (robust or intermediate) at baseline, we found some evidence of an independent association between lower 25(OH)D levels (Ͻ20 ng/ml) at baseline and a higher odds of incident frailty or death at follow-up 4.5 years later. The LASA study (8) reported that among 885 nonfrail men and women at baseline, those with 25(OH)D levels Ͻ10 ng/ml, but not those with levels between 10 -20 ng/ml, had increased odds of being classified as frail (vs. nonfrail) at the 3-yr follow-up exam, compared with that among the referent group (Ͼ20 ng/ml). In contrast, an analysis of 463 women in the Women's Health and Aging Study I (10) classified as nonfrail at baseline reported that the odds of becoming frail at follow-up did not differ between women in the lowest quartile of 25(OH)D as compared with that among women in the top three quartiles. In addition, among a While previous studies have assumed a linear inverse association between 25(OH)D levels and frailty, our findings suggest that the association between 25(OH)D and frailty status may have a U-shaped pattern with increasing odds of frailty at lower (Ͻ20 ng/ml) and higher (Ն30 ng/ml) levels. In addition, we found no evidence that higher 25(OH)D levels among nonfrail women were associated with lower risks of incident frailty or death. The cross-sectional association we observed between higher 25(OH)D levels and frailty may at least in part reflect confounding by indication as frail women might be preferentially prescribed vitamin D supplements and thus have higher levels. To address this issue, we examined the association between 25(OH)D 3 levels and frailty status because supplemental vitamin D during the study period (1992-1998) was largely reflected in 25(OH)D 2 [not 25(OH)D 3 ] levels. While our finding that higher 25(OH)D 3 levels were associated with frailty makes confounding by indication less likely, the possibility cannot be eliminated due to the observational design of our study.
Inconsistencies between the findings of studies examining the association between 25(OH)D level and frailty status may in part be explained by differences in study populations, sample size, methods to measure 25(OH)D, cut points used to define 25(OH)D status, definitions of frailty syndrome, or adequacy of adjustment for potential confounders. Strengths of this study include its large sample size, prospective analysis, measurement of total 25(OH)D using the highly accurate LC-MS/MS method, use of a validated definition of frailty status, and adjustment for multiple potential confounders. However, this study has several limitations. Participants were older Caucasian women, and results may not apply to other populations. Power was insufficient to examine the association between severe vitamin D deficiency [25(OH)D level Ͻ10 ng/ml] and frailty status. Analyses were adjusted for multiple factors, but the possibility of residual confounding cannot be eliminated. Thus, while vitamin D supplementation has been proposed as a potential therapy for the prevention and treatment of frailty (23) , the effect of vitamin D supplementation on incidence and progression of frailty, including among a target population defined by 25(OH)D status, can only be definitively addressed in a study with a randomized trial design. Surviving women not returning to clinic for repeat assessment of frailty status were slightly older at baseline but had similar health status and 25(OH)D levels. Thus, it is unlikely that missing data markedly biased our longitudinal findings toward the null hypothesis of no association. Longitudinal analyses incorporated death as a level in the ordinal frailty status outcome because death is a competing event. While our analyses are unable to determine whether the association between lower 25(OH)D levels and increased risk of incident frailty or death is due solely to the higher risk of mortality among those with lower levels, this is a plausible explanation as we found evidence of an association between baseline 25(OH)D levels and only one individual frailty component (shrinking/sarcopenia) at follow-up. Finally, measurement of 25(OH)D was performed at the baseline examination only. Thus, it was not possible to examine whether change in 25(OH)D levels was associated with incident frailty status.
Lower (Ͻ20 ng/ml) and higher (Ն30 ng/ml) 25(OH)D levels were associated with greater evidence of frailty among older women and lower 25(OH)D levels among nonfrail women at baseline were associated with an increased risk of incident frailty or death at 4.5 years. These findings suggest that frailty status should be considered as a potential outcome in trials of vitamin D supplementation in older adults.
